Financial

Analysts Give Average Recommendation of “Buy” to Histogenics Corp (NASDAQ:HSGX)

By John Miller

Shares of Histogenics Corp (NASDAQ:HSGX) have been given a consensus broker rating score of 1.50 (Buy) from the two brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and one has issued a strong buy rating on the company.

Analysts have set a 1-year consensus price target of $17.00 for the company and are predicting that the company will post ($0.49) earnings per share for the current quarter, according to Zacks. Zacks has also given Histogenics Corp an industry rank of 110 out of 265 based on the ratings given to its competitors.

A number of research firms have recently commented on HSGX. Analysts at Canaccord Genuity reiterated a “buy” rating and set a $16.50 price target on shares of Histogenics Corp in a research note on Friday, May 15th. Analysts at BTIG Research reiterated a “buy” rating and set a $13.00 price target on shares of Histogenics Corp in a research note on Thursday, May 14th. Finally, analysts at Zacks upgraded shares of Histogenics Corp from a “sell” rating to a “hold” rating and set a $9.00 price target on the stock in a research note on Tuesday, May 12th.

READ MORE HERE

Related Articles

Back to top button